Skip to main
IBIO
IBIO logo

iBio (IBIO) Stock Forecast & Price Target

iBio (IBIO) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 17%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

iBio Inc. showcases a strong potential for growth in the biotechnology sector through its innovative AI Technology Platform, which aims to enhance the development of precision antibodies while minimizing associated risks. Preclinical studies demonstrate that iBio's lead antibodies, particularly IBIO-101 and its anti-EGFRvIII antibody, exhibit significant efficacy in reducing tumor size compared to competitors, indicating promising therapeutic potential. The combination of AI-guided optimization and a bispecific approach positions iBio favorably in the market by improving the success rate of targeting hard-to-drug proteins, promising an efficient and cost-effective pathway for developing new therapies.

Bears say

iBio Inc. faces significant challenges as its preclinical successes have not translated effectively to human clinical studies, particularly in patients with Duchenne Muscular Dystrophy (DMD), where decreased myostatin levels may hinder therapeutic performance. The intense competitive landscape, with ongoing developments in treatment methods for similar diseases, presents a risk of iBio's therapies becoming obsolete or non-competitive. Additionally, the company's reliance on regulatory approvals from authorities such as the EMA and FDA introduces further uncertainty, as differing interpretations of clinical data could adversely impact product advancement and stock performance.

iBio (IBIO) has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of iBio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About iBio (IBIO) Forecast

Analysts have given iBio (IBIO) a Buy based on their latest research and market trends.

According to 6 analysts, iBio (IBIO) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

iBio (IBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.